CAS 325855-74-1
:2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-, 1'-oxide
Description:
2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-, 1'-oxide, identified by CAS number 325855-74-1, is a chemical compound that features a bipyridine core structure, which consists of two pyridine rings connected by a carbon-carbon bond. This compound is characterized by the presence of a chlorine atom at the 5-position and a methyl group at the 6-position of one pyridine ring, while the other ring is substituted with a 4-(methylsulfonyl)phenyl group at the 3-position. The presence of the methylsulfonyl group enhances its solubility and may influence its reactivity and biological activity. The 1'-oxide designation indicates that there is an oxidation at the nitrogen atom of the bipyridine structure, which can affect the compound's electronic properties and potential interactions with biological targets. Overall, this compound may exhibit interesting pharmacological properties, making it a subject of interest in medicinal chemistry and drug development.
Formula:C18H15ClN2O3S
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 8 products.
5-Chloro-6'-Methyl-3-[4-(Methylsulfonyl)phenyl]-2,3'-bipyridine 1'-Oxide
CAS:Formula:C18H15ClN2O3SPurity:98%Color and Shape:SolidMolecular weight:374.8413Etoricoxib N-Oxide 1
CAS:Formula:C18H15ClN2O3SColor and Shape:White To Off-White SolidMolecular weight:374.84Etoricoxib N1'-oxide
CAS:Controlled ProductFormula:C18H15ClN2O3SColor and Shape:NeatMolecular weight:374.84Etoricoxib N1’-Oxide
CAS:Controlled Product<p>Applications Etoricoxib N1’-Oxide is an impurity of Etoricoxib (E934100).<br>References Friesen, R., et al.: Bioorg. Med. Lett., 8, 2777 (1998), Botting, J., et al.: Drugs of Today, 35, 225 (19990, Talley, J., et al.: J. Med. Chem., 43, 775 (2000),<br></p>Formula:C18H15ClN2O3SColor and Shape:NeatMolecular weight:374.84Etoricoxib N-Oxide
CAS:<p>Etoricoxib N-Oxide is a non-steroidal anti-inflammatory drug (NSAID) that is used to treat inflammation and pain. Etoricoxib N-Oxide has a short half-life, which is due to its rapid metabolism by CYP2C9 and CYP3A4. This drug has been shown to be effective in reducing the incidence of ulcers in horses treated with it orally for 3 months. Etoricoxib N-Oxide also inhibits the production of prostaglandins, which are substances that cause pain and inflammation. NSAIDs like etoricoxib N-Oxide inhibit the activity of cyclooxygenase (COX), an enzyme that converts arachidonic acid into prostaglandins. The inhibition of COX prevents the formation of prostaglandin H2 from arachidonic acid, which is a precursor to other prostaglandins such as PGE2 and PGD2. Et</p>Formula:C18H15ClN2O3SPurity:Min. 95%Molecular weight:374.8 g/molEtoricoxib N1'-oxide
CAS:<p>EtoricoxibN1'-oxide is a metabolite of Etoricoxib. It does not inhibit COX-1 and does not significantly inhibit COX-2.</p>Formula:C18H15ClN2O3SColor and Shape:SolidMolecular weight:374.841








